Keros Therapeutics (KROS) Stock Forecast & Price Target

$17.03 +0.11 (+0.65%)

(As of 12/20/2024 05:31 PM ET)

Keros Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
4

Buy
10

Based on 14 Wall Street analysts who have issued ratings for Keros Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 4 have given a hold rating, and 10 have given a buy rating for KROS.

Consensus Price Target

$81.33
377.59% Upside

According to the 14 analysts' twelve-month price targets for Keros Therapeutics, the average price target is $81.33. The highest price target for KROS is $111.00, while the lowest price target for KROS is $44.00. The average price target represents a forecasted upside of 377.59% from the current price of $17.03.

Get the Latest News and Ratings for KROS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors.

KROS Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)	6 Buy rating(s)
Hold	4 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$81.33	$88.89	$90.63	$84.20
Forecasted Upside	377.59% Upside	58.96% Upside	66.16% Upside	120.36% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

KROS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KROS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Keros Therapeutics Stock vs. The Competition

Type	Keros Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	377.59% Upside	25,828.59% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent KROS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/16/2024	Oppenheimer 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$102.00 ➝ $63.00	+234.57%
12/16/2024	Guggenheim 2 of 5 stars	V. Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/13/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Outperform ➝ Sector Outperform	$77.00 ➝ $44.00	+144.44%
12/13/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$100.00 ➝ $47.00	+155.02%
12/12/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
12/12/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
Trump’s Sending THIS Crypto Higher on Purpose (Ad) Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW
12/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$88.00 ➝ $111.00	+65.08%
11/22/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
11/7/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Zhong Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$84.00	+24.65%
11/5/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
9/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $76.00	+37.09%
6/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+122.22%
3/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00	+59.60%
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
2/14/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:47 AM ET.

KROS Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Keros Therapeutics is $81.33, with a high forecast of $111.00 and a low forecast of $44.00.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KROS shares.
: According to analysts, Keros Therapeutics's stock has a predicted upside of 377.59% based on their 12-month stock forecasts.
: Over the previous 90 days, Keros Therapeutics's stock had 4 downgrades and 1 upgrade by analysts.
: Keros Therapeutics has been rated by research analysts at BTIG Research, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jefferies Financial Group, Oppenheimer, Scotiabank, TD Cowen, Wedbush, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Keros Therapeutics less than other "medical" companies. The consensus rating score for Keros Therapeutics is 2.71 while the average consensus rating score for "medical" companies is 2.81. Learn more on how KROS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

This page (NASDAQ:KROS) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Stock Forecast & Price Target